Login to Your Account



Second antibiotic 'GAIN' as FDA approves Cubist's MRSA-killer Sivextro

By Michael Fitzhugh
Staff Writer

Monday, June 23, 2014
Cubist Pharmaceuticals Inc. gained FDA approval Friday evening for Sivextro (tedizolid phosphate), realizing the first big payoff from its $704 million acquisition of Trius Therapeutics Inc.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription